- Home
- UPXI vs ONCT Comparison
UPXI vs ONCT Comparison
Compare UPXI & ONCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- ONCT
- Stock Information
- Founded
- UPXI 2018
- ONCT N/A
- Country
- UPXI United States
- ONCT United States
- Employees
- UPXI N/A
- ONCT N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- ONCT Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- ONCT Health Care
- Exchange
- UPXI Nasdaq
- ONCT Nasdaq
- Market Cap
- UPXI 5.3M
- ONCT 4.3M
- IPO Year
- UPXI 2021
- ONCT N/A
- Fundamental
- Price
- UPXI $4.10
- ONCT $1.13
- Analyst Decision
- UPXI Hold
- ONCT Buy
- Analyst Count
- UPXI 1
- ONCT 3
- Target Price
- UPXI $25.00
- ONCT $10.00
- AVG Volume (30 Days)
- UPXI 2.5M
- ONCT 156.9K
- Earning Date
- UPXI 11-22-2024
- ONCT 11-06-2024
- Dividend Yield
- UPXI N/A
- ONCT N/A
- EPS Growth
- UPXI N/A
- ONCT N/A
- EPS
- UPXI N/A
- ONCT N/A
- Revenue
- UPXI $83,980,115.00
- ONCT $2,161,000.00
- Revenue This Year
- UPXI $18.98
- ONCT $113.76
- Revenue Next Year
- UPXI $8.09
- ONCT N/A
- P/E Ratio
- UPXI N/A
- ONCT N/A
- Revenue Growth
- UPXI 27.11
- ONCT 227.92
- 52 Week Low
- UPXI $2.17
- ONCT $1.03
- 52 Week High
- UPXI $33.00
- ONCT $13.20
- Technical
- Relative Strength Index (RSI)
- UPXI 42.27
- ONCT 37.09
- Support Level
- UPXI $4.52
- ONCT $1.03
- Resistance Level
- UPXI $5.94
- ONCT $1.30
- Average True Range (ATR)
- UPXI 1.42
- ONCT 0.19
- MACD
- UPXI -0.34
- ONCT -0.01
- Stochastic Oscillator
- UPXI 0.58
- ONCT 13.70
About UPXI Upexi Inc.
Upexi Inc is an innovator in aggregation, accelerating Amazon and eCommerce businesses by combining consumer data and vertical integration to scale brands in multiple industries, while lowering costs with a growing distribution network.
About ONCT Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.